Agios Pharmaceuticals, Inc.
HealthcareNASDAQ:AGIO · NASDAQ Global Select
+$0.74 today
Vol 1.14M · Avg 1.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.6%
avg -27.4%
ROIC
-38.2%
avg -40.3%
ROA
-31.8%
avg -15.7%
Analysis
ROA is currently the strongest return metric at -31.8% versus its period average of -15.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian Goff | Chief Executive Officer & Director | $1.45M | — | 57 | $191,104.00 | 0.32% |
Krishnan Viswanadhan | Chief Strategy & Operations Officer | $931,509.00 | — | 47 | $10,282.00 | 0.02% |
Sarah Gheuens | Chief Medical Officer and Head of Research & Development | $887,232.00 | — | 46 | $8,500.00 | 0.01% |
Tsveta Milanova | Chief Commercial Officer | $836,643.00 | — | 48 | $46,829.00 | 0.08% |
Cecilia Jones | Chief Financial Officer | $791,835.00 | — | 51 | $58,139.00 | 0.10% |
James William Burns | Chief Legal Officer | $780,510.00 | — | 48 | $8,500.00 | 0.01% |
Craig Thompson | Co-Founder | $50,000.00 | — | 73 | — | — |
Tak Wah Mak FRSC | Co-Founder | $50,000.00 | — | 80 | — | — |
Shin-San Su | Co-Founder | $50,000.00 | — | 70 | — | — |
Lewis Clayton Cantley | Co-Founder | $50,000.00 | — | 77 | — | — |
Steven Vickers | Vice President of Sales | — | — | — | — | — |
T. J. Washburn | Vice President, Controller & Principal Accounting Officer | — | — | 44 | $868.00 | <0.01% |
Clive Patience | Chief Technical Operations Officer | — | — | 62 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
55
$6.19M
Net Sentiment
$6.19M
Net selling
Most Active
Gheuens Sarah
12 transactions
1–10 of 55
Analysis
Insiders reported 0 buys worth $0.00 and 55 sells worth $6.19M over the last 12 months. That adds up to net selling of $6.19M. Gheuens Sarah was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +33.0% | +17.8% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.0% over three years. Forward estimates point to Revenue at +17.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Galapagos N.V.
GLPG
$1.84B
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
$1.62B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
Who manages AGIO?
Agios Pharmaceuticals, Inc. (AGIO) lists 13 active executives. The top listed executive is Craig Thompson, Co-Founder.
Are AGIO insiders buying or selling?
Recent insider activity shows net buying of $8.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.